1. Home
  2. RNA vs HASI Comparison

RNA vs HASI Comparison

Compare RNA & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNA
  • HASI
  • Stock Information
  • Founded
  • RNA 2012
  • HASI 1981
  • Country
  • RNA United States
  • HASI United States
  • Employees
  • RNA N/A
  • HASI N/A
  • Industry
  • RNA Biotechnology: Pharmaceutical Preparations
  • HASI Real Estate Investment Trusts
  • Sector
  • RNA Health Care
  • HASI Real Estate
  • Exchange
  • RNA Nasdaq
  • HASI Nasdaq
  • Market Cap
  • RNA 3.6B
  • HASI 3.4B
  • IPO Year
  • RNA 2020
  • HASI 2013
  • Fundamental
  • Price
  • RNA $31.45
  • HASI $27.20
  • Analyst Decision
  • RNA Strong Buy
  • HASI Strong Buy
  • Analyst Count
  • RNA 14
  • HASI 9
  • Target Price
  • RNA $67.71
  • HASI $38.33
  • AVG Volume (30 Days)
  • RNA 1.6M
  • HASI 1.8M
  • Earning Date
  • RNA 08-08-2025
  • HASI 07-31-2025
  • Dividend Yield
  • RNA N/A
  • HASI 6.07%
  • EPS Growth
  • RNA N/A
  • HASI N/A
  • EPS
  • RNA N/A
  • HASI 1.08
  • Revenue
  • RNA $8,927,000.00
  • HASI $126,702,000.00
  • Revenue This Year
  • RNA N/A
  • HASI $189.49
  • Revenue Next Year
  • RNA $156.80
  • HASI $14.03
  • P/E Ratio
  • RNA N/A
  • HASI $25.37
  • Revenue Growth
  • RNA N/A
  • HASI N/A
  • 52 Week Low
  • RNA $21.51
  • HASI $21.98
  • 52 Week High
  • RNA $56.00
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • RNA 56.75
  • HASI 54.56
  • Support Level
  • RNA $27.98
  • HASI $26.36
  • Resistance Level
  • RNA $29.70
  • HASI $27.92
  • Average True Range (ATR)
  • RNA 1.43
  • HASI 0.81
  • MACD
  • RNA 0.26
  • HASI 0.03
  • Stochastic Oscillator
  • RNA 77.30
  • HASI 63.64

About RNA Avidity Biosciences Inc.

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: